- $1.33bn
- $2.72bn
- $588.90m
Alvotech settles with J&J to launch Stelara biosimilar in Europe, Canada (updated)
Alvotech reaches settlements with J&J for Stelara biosimilar launch
U.S. STOCKS ON THE MOVE-Sarepta, Hershey, Dollar Tree
U.S. STOCKS ON THE MOVE-Overseas Shipholding, Palisade Bio, Archer-Daniels-Midland
Alvotech rises as biosimilar candidate meets main goal of study
Alvotech rises on regulatory update for Humira and Stelara biosimilars
U.S. STOCKS ON THE MOVE-Virgin Galactic, Meta Platforms, EchoStar
U.S. STOCKS ON THE MOVE-Palo Alto Networks, Masimo, Tigo Energy
U.S. STOCKS ON THE MOVE-Intuitive Surgical, Home Depot, SMART Global
U.S. STOCKS ON THE MOVE-Aehr Test Systems, chipmakers, crypto stocks
Alvotech near one-month high on EU backing for Stelara biosimilar
J&J upbeat on 2023 as devices rebound post-COVID, shares jump (updated)
U.S. STOCKS ON THE MOVE-Micron, Greenbrier, Immunome
U.S. STOCKS ON THE MOVE-Sigilon, Netflix, RenovoRx
Alvotech falls as U.S. FDA declines to approve biosimilar to Humira
Brief: Alvotech And Teva Secure U.S. License Date For AVT04
Alvotech and partner Teva slip as FDA snubs RA drug
Teva falls after FDA declines to approve drug with partner Alvotech
Alvotech up on deal to commercialize Novartis' biosimilar asthma drug